GJL
SEEL

Gendell Jeffrey L’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Gendell Jeffrey L’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,351
Closed -$254K – 104
2024
Q1 		$254K Buy
3,351
+2,479
+284% +$327K 0.01% 86
2023
Q4 		$155K Sell
872
-884
-50% -$435K 0.01% 77
2023
Q3 		$1.24M Buy
1,756
+410
+30% +$1.76M 0.07% 64
2023
Q2 		$6.18M Buy
1,346
+26
+2% +$90.2K 0.48% 25
2023
Q1 		$3.5M Buy
1,320
+42
+3% +$123K 0.33% 37
2022
Q4 		$3.33M Hold
1,278
– – 0.3% 37
2022
Q3 		$5.06M Hold
1,278
– – 0.66% 23
2022
Q2 		$3.34M Sell
1,278
-7
-0.5% -$18.2K 0.39% 34
2022
Q1 		$4.13M Buy
1,285
+647
+101% +$2.78M 0.3% 38
2021
Q4 		$3.99M Buy
638
+154
+32% +$1.18M 0.32% 29
2021
Q3 		$4.48M Buy
484
+30
+7% +$258K 0.38% 28
2021
Q2 		$4.6M Buy
454
+135
+42% +$2.22M 0.41% 27
2021
Q1 		$6.11M Buy
+319
New +$3.72M 0.65% 18

Other funds holding SEEL

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CHA
Carmichael Hill & Associates Gaithersburg, Maryland $282M AUM 32.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gendell Jeffrey L's SEEL Position: Q2 2024 in Review

Gendell Jeffrey L sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2024, closing a stake of 3,351 shares — an estimated $254K sold.

Gendell Jeffrey L first reported a position in SEEL in Q1 2021 and held it in 13 quarters. The position peaked at $6.18M in Q2 2023. 18 funds tracked by Wall St. Rank hold SEEL as of Q2 2024.

  • Gendell Jeffrey L reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Gendell Jeffrey L sold 3,351 Seelos Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $254K.
  • Gendell Jeffrey L first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
  • Gendell Jeffrey L's Seelos Therapeutics, Inc. Common Stock position peaked at $6.18M in Q2 2023.
  • 18 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Gendell Jeffrey L's 13F filing for Q2 2024, filed 14 Aug 2024.